Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 11/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.39 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25250527 | 1.00 | BACE1 (1.00) | BACE1KMT2ALMNAMAPTPDK2 | |
| SCHEMBL3667620 | 1.00 | BACE1 (1.00) | BACE1KMT2ALMNAMAPTPDK2 | |
| SCHEMBL25756470 | 1.00 | BACE1 (1.00) | BACE1KMT2ALMNAMAPTPDK2 | |
| SCHEMBL30471238 | 0.84 | BACE1 (0.72) | BACE1LMNAMAPTPDK2PDK4 | |
| SCHEMBL24458972 | 0.83 | BACE1 (0.71) | BACE1KMT2AIDO1 | |
| SCHEMBL24448446 | 0.83 | BACE1 (0.71) | BACE1KMT2AIDO1 | |
| SCHEMBL24459149 | 0.83 | BACE1 (0.70) | BACE1KMT2APDK2PDK4IDO1 | |
| SCHEMBL30536706 | 0.83 | BACE1 (0.70) | BACE1KMT2APDK2PDK4IDO1 | |
| SCHEMBL24403333 | 0.83 | BACE1 (0.70) | BACE1KMT2APDK2PDK4IDO1 | |
| SCHEMBL26312575 | 0.83 | BACE1 (0.70) | BACE1KMT2APDK2PDK4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346805-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2240483-B1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2013-02-27 | — | — | EP | disclosed |
| US-8324221-B2 | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2240483-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | Array Biopharma, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089454-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053959-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | AKT1, AKT2, PIK3CA | BACE1 1628/4885KMT2A 3145/4885LMNA 2904/4885 |
| US-20130072500-A1 | PYRIMIDYL CYCLOPENTANES AS AKT PROTEIN KINASE INHIBITORS | PIK3CA, AKT1, AKT2 | BACE1 1617/4885KMT2A 2999/4885LMNA 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.